An IMS Institute analysis shows that more than 80% of 168 drug shortages involve generic products, and more than 80% affect injectable treatments. Two-thirds treat cancer, infection, heart illness, diseases of the central nervous system and pain. The report includes data on the supply chain and calls for early shortage notification.

Related Summaries